In this context, some experiences have shown that a comprehensive treatment approach of surgery combined withhyperthermic intraperitoneal chemotherapy (HIPEC) could beable to improve the prognosis of AEOC as reported in few clinical studies. Despite the established rationale and these encouraging results, a certain degree of skepticism still surrounds HIPEC in AEOC, involving inherent potential morbidityand the paucity of randomized data confirming its theoreticaladvantage. Moreover, the literature on HIPEC safety and efficacyin combination with bevacizumab is very less and thereforeneeds to be better investigated. Based on these considerations,we conducted a phase II monocentric, open label, non-randomized and single-arm study aimed to explore the feasibility ofPDS and HIPEC upfront followed by first-line therapy with bevacizumab, as GOG-0218 schedule